


# GSK FY 2018 results

All % at constant exchange rates (CER)

GSK delivers sales, earnings and cash flow growth in 2018



Numbers do not add to the total because they have been rounded to the nearest £0.1bn

See [press release](http://www.gsk.com) on [www.gsk.com](http://www.gsk.com) for full details on FY 2018.

Please read the cautionary statement regarding **forward-looking statements** and the definitions and reconciliations for non-IFRS measures on pages 4-5 and 44-45 of the press release.

CER% represents growth at constant exchange rates.

For a full explanation please see page 44 of the press release.

Total Group operating margin  
**17.8%**

+5.0%pts

Adjusted Group operating margin  
**28.4%**

+0.5%pts

Total EPS  
**73.7p**

+ >100%


Adjusted EPS  
**119.4p**

+12%

Free cash flow  
**£5.7bn**

2017: £3.5bn

2018 dividend  
**80p**



Immune system T-cells attacking a cancer cell